Vapen MJ Ventures (VAPN.C) knows that inhalers are a perfect alternative to ingesting cannabis for people who cannot stand smoking weed, and that’s why they’ve released their line of CBD-inhalers this week.
Traditionally, inhalers are associated with asthma and other respiratory ailments, but Vapen has taken the technology and bent it to their will.
And the market prospects behind CBD aren’t bad either:
The CBD market, estimated to be worth $20 billion by 2024 by CBD Analytics, is the place to be if you’re a small-cap company looking to make a big splash in a new industry.
“Expanding our product lines into the rapidly growing CBD market will strengthen the Vapen brand and expand our market reach to consumers seeking CBD benefits. This strategy aligns with our long-term growth plans to enhance our product offering, increase our brand awareness and grow our distribution to drive shareholder value,” said Thai Nguyen, founder and chief executive officer of Vapen MJ.
Inhalers work because all cannabis inhalers contain an attached vaporizer, which allows users to fill in their ideal doses of a cannabis extract or concentrate. In this case, the pre-set amounts of THC (or CBD) are limited to 10 mg by law, with each puff producing the same measurable effect.
The inhaler technology specifically offers a precisely measured dose of CBD in three flavours—raw, bubblegum and strawberry—and comes in a 1,000 milligram canister. It retails for USD$80, which isn’t bad when you consider that each puff is 10 mg with a total of 100 puffs per inhaler.
Here’s a video review of their THC line of puffers:
What is Vapen MJ
Maybe we’re getting ahead of ourselves here, though. Vapen’s a relatively new player in the cannabis space, having only joined the CSE on March 13, so maybe it would be best if we ran something of an introduction.
Vapen MJ, through its wholly owned subsidiaries, currently operates as an agricultural technology, services and property management company utilizing a full-vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (tetrahydrocannabinol and cannabidiol vape cartridges, concentrates and edibles), retail dispensary and wholesale distribution of high-margin cannabis THC and hemp CBD products.
Since their arrival on the CSE, the company has partnered with Pegasus for production, extraction and sale of cannabis THC products in Las Vegas, Nevada dispensaries. The operation is expected to go live in the fall under the Vapen brand.
Pegasus operates a successful cultivation center that distributes its Virtue Brand cannabis products to dispensaries in Las Vegas.
Their products will include:
- Vapen THC cartridges;
- Vapen extracts (connoisseur concentrates);
- Vapen kitchen edibles — snacks, candies, gummies, chocolate bars.
The specifics of the arrangement have Vapen MJ providing managerial services and standard operating procedures for production and extraction, including employee onboarding and training. Vapen is also handling the bulk tolling (extraction) for other brands. Meanwhile, Pegasus and their partners will supply financing for the equipment, working capital and biomass.
Shares of Vapen MJ rose $0.07 today to close at $1.65.
They have 18,674,626 shares issued and outstanding and a market cap of $29.5 million.
Full Disclosure: Vapen MJ Ventures is an equity.guru marketing client.